Subscribe
gustavo-frazao-shutterstock-com-patent-
Gustavo Frazao / Shutterstock.com
12 August 2016Americas

Horizon accuses Actavis of infringing Vimovo patents

Horizon Pharma has filed a complaint against Actavis accusing it of infringing three of patents for the Vimovo (naproxen/esomeprazole magnesium) drug.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Federal Circuit invalidates Nuvo’s Vimovo patents
17 May 2019   The US Court of Appeals for the Federal Circuit has delivered a blow to Nuvo Pharmaceuticals by reversing a decision which had upheld the validity of the Canadian company’s pain relief drug Vimovo.


Editor's picks

Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024

Editor's picks

Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024

More on this story

Americas
Federal Circuit invalidates Nuvo’s Vimovo patents
17 May 2019   The US Court of Appeals for the Federal Circuit has delivered a blow to Nuvo Pharmaceuticals by reversing a decision which had upheld the validity of the Canadian company’s pain relief drug Vimovo.

More on this story

Americas
Federal Circuit invalidates Nuvo’s Vimovo patents
17 May 2019   The US Court of Appeals for the Federal Circuit has delivered a blow to Nuvo Pharmaceuticals by reversing a decision which had upheld the validity of the Canadian company’s pain relief drug Vimovo.

More features

GSK: ‘Whoever moves first has UPC advantage’
Pfizer and BioNTech win UK COVID-19 dispute
Roche to outside counsel: ‘Law firms must adapt to the modern world’
Astellas defends blockbuster cancer treatment patent
Regeneron denied safe harbour defence in COVID-19 drug dispute
How to navigate patent term adjustment in China
Moderna wins reprieve in COVID-19 vaccine dispute
Boehringer sues Indian manufacturer over diabetes drug generic